NCT07682363 Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
| NCT ID | NCT07682363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novo Nordisk A/S |
| Condition | Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 470 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2027-02-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 470 participants in total. It began in 2026-06-03 with a primary completion date of 2027-02-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology / hepatology / infection / gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.
Eligibility Criteria
Inclusion Criteria: * Has provided informed consent. * Registered clinical practice location in provincial capital or municipality. * Physician with a license for clinical practice. * Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology. * Hospital level: Grade IIIA hospital. * Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years). * Conducts outpatient clinics for at least 1 half-days per week. * The patient load of MASLD/MASH per month in the department should be: * a. Endocrinology ≥20 patients per month * b. Hepatology/Gastroenterology/ Infectious ≥30 patients per month Exclusion Criteria: -Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.
Contact & Investigator
Clinical Transparency (dept. 2834)
STUDY DIRECTOR
Novo Nordisk A/S
Frequently Asked Questions
Who can join the NCT07682363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07682363 currently recruiting?
Yes, NCT07682363 is actively recruiting participants. Contact the research team at clinicaltrials@novonordisk.com for enrollment information.
Where is the NCT07682363 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07682363 clinical trial?
NCT07682363 is sponsored by Novo Nordisk A/S. The principal investigator is Clinical Transparency (dept. 2834) at Novo Nordisk A/S. The trial plans to enroll 470 participants.